statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Revance Therapeutics, Inc. (NASDAQ: RVNC), today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update. Financial Highlights In connection with the...

Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update

Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market. Revance will host a...

Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024

Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced two poster presentations on DAXXIFY for the treatment of cervical dystonia at the annual meeting of American Academy of Neurology (AAN...

Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting

For the last three days, A.I.dvisor has detected that RVNC's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Revance Therapeutics (RVNC, $4.73) Aroon Indicator entered a Downtrend on April 01, 2024.

Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced new hire grants totaling an aggregate of 222,452 inducement restricted stock units (RSUs) to 29 employees. The RSUs vest over four years...

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

This is a signal that RVNC's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

Revance Therapeutics (RVNC, $5.42) Stochastic Oscillator left the oversold zone on March 14, 2024

This is a Bearish indicator signaling RVNC's price could decline from here. Traders may explore shorting the stock or put options...

Revance Therapeutics (RVNC, $5.42) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 14, 2024

This indicator may be signaling that RVNC's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Revance Therapeutics (RVNC, $5.42) entered Downtrend as Momentum indicator drops below 0 level on Mar 14, 2024

Revance Therapeutics, Inc. (NASDAQ:RVNC  Get Free Report) shares were down 3.8% on Tuesday . The company traded as low as $5.92 and last traded at $6.02. Approximately 159,732 shares changed...

Revance Therapeutics (NASDAQ:RVNC) Trading Down 3.8%

Revance Therapeutics, Inc. (NASDAQ:RVNC  Get Free Report) has received an average recommendation of Moderate Buy from the eight ratings firms that are currently covering the...

Revance Therapeutics, Inc. (NASDAQ:RVNC) Given Consensus Recommendation of "Moderate Buy" by Analysts

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.

Watchers	2,761
52-Wk Low	$3.00
52-Wk High	$33.10

Volume	1.68M
52-Wk High	$33.10
52-Wk Low	$3.00

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.36	--	--	N/A
Q1'24	-$0.46	-$0.44	4.11%	BEAT
Q4'23	-$0.65	-$0.50	23.89%	BEAT
Q3'23	-$0.69	-$0.39	44.16%	BEAT
Q2'23	-$0.63	-$0.56	11.56%	BEAT

RVNC Revance Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals